Sub-Navigation

• Investor News
• Ad-hoc Publications
• Archive

Bayer Links

• Bayer Global
• Nachhaltigkeit
• Presse
• Bayer in Social Media

Additionals

• General Conditions of Use
• Privacy Statement
• Imprint
• Technical Details

Klickpfad

• Home
• News
• Investor News

Search

To view the PDF documents you will need the Acrobat Reader. Please click here to download the free Adobe Acrobat Reader software.

Receive our IR News via E-Mail, RSS Feed or SMS.

Friday January 27, 2012

Milestone for stacked insect-resistant, herbicide-tolerant cotton

Bayer CropScience's TwinLink® cotton technology receives full authorization in the US

Wednesday January 18, 2012

Not intended for UK and US Media - Stroke Prevention in Patients with Atrial Fibrillation:

Bayer's Xarelto® Approved in Japan for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation

Wednesday January 18, 2012

Not intended for U.S. and UK Media (LBA #385) - Results of pivotal Phase III study in patients with metastatic colorectal cancer:

Positive Phase III Data on Bayer's Investigational Drug Regorafenib Show Significant Increase in Overall Survival

First presentation of data from CORRECT trial as "Late Breaking Abstract" at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI)

Tuesday January 10, 2012

Not intended for US Media: Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI):

Phase III Data of Bayer's Regorafenib in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Oral Presentation at 2012 ASCO-GI Congress

Late breaking abstract (LBA #385) of Phase III CORRECT study results to be presented on January 21, 2012